RxDoctor Payments Data

Yetzenia Arauz

Nurse Practitioner · Fairmont City, ILNPI 1366508053

Payments from drug & device makers

$908in general payments, 2019–2025

Across 38 payments — averaging $23.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$261
  • Boehringer Ingelheim$141
  • Lilly USA, LLC$134
  • Amgen$87
  • AbbVie$51
  • AstraZeneca$50
  • plus $185 from 7 others

What the payments were for

  • Food & beverage$908100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$908 in reported general payments places this provider in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$584
Medicare patients
19
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate23$24,864
FarxigaDapagliflozin Propanediol21$21,963
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$5,620
Gabapentin63$1,246
Famotidine41$799
Fluticasone Propionate40$622
Oxybutynin Chloride15$319
Atorvastatin Calcium69$302
Colchicine13$259
Levothyroxine Sodium24$239
Pravastatin Sodium26$187
Tamsulosin Hcl41$185
Metoprolol Succinate29$185
Metformin Hcl51$177
Finasteride34$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$22$24,86423 claims
AstraZenecaFarxiga$50$21,96321 claims
GSKTrelegy Ellipta$38$5,62011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Fairmont City

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →